These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36103248)

  • 1. Real-world effectiveness and safety of insulin glargine 300 U/ml in insulin-naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS.
    Vargas-Uricoechea H; Burga Nuñez JL; Rosas Guzmán J; Silva-Gomez L; Beltran S; Sañudo-Maury ME
    Diabetes Obes Metab; 2023 Jan; 25(1):238-247. PubMed ID: 36103248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.
    Galstyan GR; Tirosh A; Vargas-Uricoechea H; Mabunay MA; Coudert M; Naqvi M; Pilorget V; Khan N
    Diabetes Ther; 2022 Jun; 13(6):1187-1202. PubMed ID: 35532858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting.
    Pfohl M; Jornayvaz FR; Fritsche A; Pscherer S; Anderten H; Pegelow K; Seufert J
    Diabetes Obes Metab; 2020 May; 22(5):759-766. PubMed ID: 31903680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
    Seufert J; Wiesli P; Fritsche A; Anderten H; Pegelow K; Pscherer S; Pfohl M
    Diabetes Obes Metab; 2022 Jan; 24(1):72-81. PubMed ID: 34514696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
    Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
    Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR; Traylor L; Mullins P; Landgraf W
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
    Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
    BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
    Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland.
    Thomann R; Zechmann S; Alexander-David N; Jornayvaz FR
    Diabetes Metab Syndr Obes; 2020; 13():2359-2365. PubMed ID: 32753920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study.
    Sethi B; Al-Rubeaan K; Unubol M; Mabunay MA; Berthou B; Pilorget V; Vethakkan SR; Frechtel G
    Diabetes Ther; 2022 Jul; 13(7):1395-1408. PubMed ID: 35713873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.